Endometrial papillary serous carcinoma: Patterns of spread and treatment

Clinical Obstetrics and Gynecology

Volumn 39, Issue 3, 1996, Pages 686-695

  Nicklin, James L ^a,b   Copeland, Larry J ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NONE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; MEDROXYPROGESTERONE; MEGESTROL; PLATINUM; PROGESTERONE; TAMOXIFEN;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURGERY; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; METASTASIS; PROGNOSIS; REVIEW;

ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; CYSTADENOCARCINOMA, PAPILLARY; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0029778221     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-199609000-00016     Document Type: Review

References (34)

1. Kurman RJ, Zaino RJ, Norris HJ. Endometrial Carcinoma. In: Kurman RJ, ed. Blausteins's Pathology of the Female Genital Tract, 4th ed. New York: Springer-Verlag, 1994:439-486.
2. Dunton CJ, Gulnar B, McFarland M, Hernandez E. Uterine papillary serous carcinoma: a review. Obstet Gynecol Surv. 1991;46:97-102.
3. Hendrickson M, Ross J, Martinez A, Eifel P, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982;6:93-108.
4. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma: a morphologically diverse neoplasm with unifying clinicopathological features. Am J Surg Pathol. 1992;16:600-610.
5. Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol. 1992;47:298-305.
6. O'Hanlon KA, Levine PA, Harbatkin D, et al. Virulence of papillary endometrial carcinoma. Gynecol Oncol. 1990;37:112-119.
7. Williams KE, Waters ED, Woolas RP, Hammond IG, McCartney AJ. Mixed serous-endometrioid carcinoma of the uterus: pathologic and cytopathologic analysis of a high-risk endometrial carcinoma. Int J Gynecol Cancer. 1994;4:7-18.
8. Chambers JT, Merino M, Kohorn EI, Peschel RE, Schwartz PE. Uterine papillary serous carcinoma. Obstet Gynecol. 1987;69:109-113.
9. Parkash V, Carcangiu ML. Uterine papillary serous carcinoma after radiation therapy for carcinoma of the cervix. Cancer. 1992;69:496-501.
10. Gitsch G, Friedlander ML, Wain GV, Hacker NF. Uterine papillary serous carcinoma. Cancer. 1995;75:2239-2243.
11. Hendrickson MR, Longacre TA, Kempson RL. Uterine papillary serous carcinoma revisited (editorial). Gynecol Oncol. 1994;54:261-263.
12. Goff BA, Kalo D, Schmidt RA, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol. 1994;54:264-268.
13. Christman JE, Kapp DS, Hendrickson MR, Howes AE, Ballon SC. Therapeutic approaches to uterine papillary serous carcinoma: a preliminary report. Gynecol Oncol. 1987;26:228-235.
14. Abeler VM, Kjorstad KE. Serous Papillary carcinoma of the endometrium: a histopathological study of 22 cases. Gynecol Oncol. 1990;39:266-271.
15. Hamaguchi K, Komai K, Sakihama H, Okura N, Nagasue N, Nisida T, Yakushiji M. Chemotherapeutic approach to uterine papillary serous carcinoma. Asia-Oceania J Obstet Gynecol. 1990;16:367-372.
16. Levenback C, Burke TW, Silva E, Morris M, Gershenson DM, Kavanagh JJ, Wharton JT. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol Oncol. 1992;46:317-321.
17. Carcangiu ML, Chambers JT. Early pathological stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathological features and survival. Int J Gynecol Pathol. 1995;14,30-38.
18. Lee KR, Belinson JL. Recurrence in non-invasive endometrial carcinoma: relationship to uterine papillary serous carcinoma. Am J Surg Pathol. 1991;15:965-973.
19. Rosenberg P, Blom R, Hogberg T, Simonsen E. Death rate and recurrence pattern among 841 clinical stage 1 endometrial cancer patients with special reference to uterine papillary serous carcinoma. Gynecol Oncol. 1993;51:311-315.
20. Gallion HH, van Nagell JR, Powell DF, et al. Stage 1 serous papillary carcinoma of the endometrium. Cancer. 1989;63:2224-2228.
21. Price FV, Chambers SK, Carcangiu ML, Kohorn EI, Schwartz PE, Chambers JT. Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 1993;51:383-389.
22. Tseng PC, Sprance HE, Carcangiu ML, Chambers JT, Schwartz PE. CA-125, NB/70K and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma. Obstet Gynecol. 1989;74:384-386.
23. Fukuma K, Miyamura S, Thoya T, Tanaka N, Fujisaki S, Okamura H, Maeyama M. Uterine papillary serous carcinoma with high levels of serum carcinoembryonic antigen. Cancer. 1987;59:403-405.
24. Prat J, Oliva E, Lerma E, Vaquero M, Matias-Guiu X. Uterine papillary serous adenocarcinoma. Cancer. 1994;74:1778-1783.
25. King SA, Adas AA, LiVolsi VA, et al. Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma. Cancer. 1995;75:2700-2705.
26. Miller B, Umpierre S, Tornos C, Burke T. Histologic Characterization of uterine papillary serous adenocarcinoma. Gynecol Oncol. 1995;56:425-429.
27. Umpierre SA, Burke TW, Tornos C, Ordonez N, Levenback C, Morris M. Immunocytochemical analysis of uterine papillary serous carcinomas for estrogen and progesterone receptors. Int J Gynecol Path. 1994;13:127-130.
28. Carcangiu ML, Chambers JT, Voynick IM, Pirro M, Schwartz PE. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part 1: clinical and histological correlations. Am J Clin Pathol. 1990;94:247-254.
29. Trope C, Johnsson JE, Simonsen E, Christiansen H, Cavallin-Stahl E, Horvath G. Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin. Am J Obstet Gynecol. 1984;149:379-381.
30. Fitzgerald G, Rosenthal S. Uterine papillary serous carcinoma: complete response to combination chemotherapy. Cancer. 1985;59:403-405.
31. Frank AH, Tseng PC, Haffty BG, et al. Adjuvant whole-abdominal radiation therapy in uterine papillary serous carcinoma. Cancer. 1991;68:1516-1519.
32. Mallipeddi P, Knapp DS, Nelson NNH. Long-term survival with adjuvant whole abdominopelvic irradiation for uterine papillary serous carcinoma. Cancer. 1993;71:3076-3081.
33. Rosenburg P, Boeryd B, Simonsen E. A new aggressive treatment approach to high-grade endometrial cancer of possible benefit to patients with stage 1 uterine papillary cancer. Gynecol Oncol. 1993;48:32-37.
34. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Look KY, Partridge EE. A phase III trial comparing cisplatin/cytoxan (PC) and cisplatin/taxol (PT) in advanced ovarian cancer (AOC) (abstract). ASCO, Los Angeles, CA, May 20-25, 1995.